Trial Profile
A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2020
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Bausch Health Companies
- 23 Mar 2020 Results summarizing malignancy rates in psoriasis clinical studies of brodalumab (NCT00975637; NCT01101100; NCT01708590 (AMAGINE-1); NCT01708603 (AMAGINE-2); NCT01708629 (AMAGINE-3).) published in the American Journal of Clinical Dermatology
- 06 Sep 2019 Protocol has been amended at week 123 that allowed patients with an inadequate response during treatment with brodalumab 140 mg Q2W to have their dose increased to 210 mg Q2W, according to results published in the American Journal of Clinical Dermatology.
- 06 Sep 2019 Results published in the American Journal of Clinical Dermatology